CTT Pharmaceutical Holdings, Inc. filed a Statement of Changes in Beneficial Ownership on November 6, 2026, disclosing a purchase of 9,000 shares of CTTH common stock by the company's CEO and Director, Ryan Khouri, on November 4, 2026.

Key Highlights

  • Reporting person: CTT Pharmaceutical Holdings, Inc., represented by Ryan Khouri, serving as CEO and Director
  • Transaction: 9,000 shares of CTTH acquired (transaction code P, indicating an open-market purchase)
  • Price per share: $0.05
  • Transaction date: November 4, 2026
  • Post-transaction ownership: 9,452,536 shares held directly following the reported purchase
  • No derivative securities were reported in Table II of the filing

Ryan Khouri's Share Purchase at CTT Pharmaceutical Holdings

According to the filing, Ryan Khouri, who serves as both CEO and Director of CTT Pharmaceutical Holdings, Inc. (OTC:CTTH), acquired 9,000 shares of the company's common stock on November 4, 2026, at a price of $0.05 per share. The transaction was coded "P," indicating a purchase on the open market. The filing was submitted on November 6, 2026, and covers a single non-derivative transaction recorded in Table I.

Following the reported transaction, the filing states that Khouri directly holds 9,452,536 shares of CTTH. CTT Pharmaceutical Holdings, Inc. is a pharmaceutical company incorporated and headquartered in Tampa, Florida, with its registered address listed as 1646 W. Snow Ave Suite 138, Tampa, Florida 33606. No derivative securities, such as options, warrants, or convertible instruments, were reported in Table II of this filing. The filing was made by one reporting person and was not indicated as an amendment to a prior filing.

What Was Disclosed

The filing disclosed a purchase of 9,000 shares of CTT Pharmaceutical Holdings common stock at $0.05 per share by CEO and Director Ryan Khouri on November 4, 2026, bringing his directly held total to 9,452,536 shares, with no derivative securities reported.